Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges

S.T.H.P. Bolhaar; M.M. Tiemessen; L. Zuidmeer; A. van Leeuwen; K. Hoffmann-Sommergruber; C.A.F.M. Bruijnzeel - Koomen; L.S. Taams; E.F. Knol; E. van Hoffen; R. van Ree; A.C. Knulst

doi:10.1111/j.1365-2222.2004.1939.x

Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges

S.T.H.P. Bolhaar, M.M. Tiemessen, L. Zuidmeer, A. van Leeuwen, K. Hoffmann-Sommergruber, C.A.F.M. Bruijnzeel - Koomen, L.S. Taams, E.F. Knol, E. van Hoffen, R. van Ree, A.C. Knulst

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The effect of birch-pollen immunotherapy (IT) on cross-reactive food allergies is controversial.

OBJECTIVE: The aim of this study was to investigate the effect of birch-pollen IT on apple allergy and to evaluate recombinant allergens and double-blind placebo-controlled food challenges (DBPCFCs) as monitoring tools.

METHODS: Twenty-five adult birch-pollen- and apple-allergic patients were randomly divided into two groups, either receiving birch-pollen IT or symptomatic drugs only. IgE and IgG4 antibodies against birch pollen, apple, natural Bet v 1 and Mal d 1 were measured. In addition, skin prick tests (SPT) were performed using recombinant Bet v 1 (rBet v 1) and Mal d 1 (rMal d 1). Clinical outcome was evaluated by DBPCFC. CD4(+)CD25(+) regulatory T cells (Tregs) were isolated from peripheral blood and tested in functional assays.

RESULTS: Birch-pollen IT resulted in a significant decrease of SPT reactivity for rBet v 1 (30-fold) and rMal d 1 (10-fold) already after 3 months. IgG4 antibodies were potently induced against Bet v 1, displaying cross-reactivity to Mal d 1. Visual analogue scale scores decreased >10-fold in 9/13 patients of the IT group, with three patients converting to negative. In the control group, no decrease was observed. Birch-pollen IT did not lead to detectable changes in the number or function of the CD4(+)CD25(+) Tregs.

CONCLUSIONS: This trial supports the claims that birch-pollen IT also decreases allergy to foods containing Bet v 1-homologous allergens. Recombinant allergens and DBPCFCs have proven to be useful tools for monitoring the effect of birch-pollen IT on linked food allergies.

Original language	English
Pages (from-to)	761-769
Number of pages	9
Journal	Clinical and Experimental Allergy
Volume	34
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2222.2004.1939.x
Publication status	Published - 2004

Keywords

Adult
Allergens
Antigens, Plant
Betula
CD4-Positive T-Lymphocytes
Cross Reactions
Desensitization, Immunologic
Double-Blind Method
Female
Food
Food Hypersensitivity
Humans
Immunologic Tests
Lymphocyte Activation
Male
Malus
Plant Proteins
Pollen
Recombinant Proteins
Skin Tests

Access to Document

10.1111/j.1365-2222.2004.1939.x

Cite this

Bolhaar, S. T. H. P., Tiemessen, M. M., Zuidmeer, L., van Leeuwen, A., Hoffmann-Sommergruber, K., Bruijnzeel - Koomen, C. A. F. M., Taams, L. S., Knol, E. F., van Hoffen, E., van Ree, R., & Knulst, A. C. (2004). Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clinical and Experimental Allergy, 34(5), 761-769. https://doi.org/10.1111/j.1365-2222.2004.1939.x

@article{22e81715ecc3438c874542e5f4e65291,

title = "Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges",

abstract = "BACKGROUND: The effect of birch-pollen immunotherapy (IT) on cross-reactive food allergies is controversial.OBJECTIVE: The aim of this study was to investigate the effect of birch-pollen IT on apple allergy and to evaluate recombinant allergens and double-blind placebo-controlled food challenges (DBPCFCs) as monitoring tools.METHODS: Twenty-five adult birch-pollen- and apple-allergic patients were randomly divided into two groups, either receiving birch-pollen IT or symptomatic drugs only. IgE and IgG4 antibodies against birch pollen, apple, natural Bet v 1 and Mal d 1 were measured. In addition, skin prick tests (SPT) were performed using recombinant Bet v 1 (rBet v 1) and Mal d 1 (rMal d 1). Clinical outcome was evaluated by DBPCFC. CD4(+)CD25(+) regulatory T cells (Tregs) were isolated from peripheral blood and tested in functional assays.RESULTS: Birch-pollen IT resulted in a significant decrease of SPT reactivity for rBet v 1 (30-fold) and rMal d 1 (10-fold) already after 3 months. IgG4 antibodies were potently induced against Bet v 1, displaying cross-reactivity to Mal d 1. Visual analogue scale scores decreased >10-fold in 9/13 patients of the IT group, with three patients converting to negative. In the control group, no decrease was observed. Birch-pollen IT did not lead to detectable changes in the number or function of the CD4(+)CD25(+) Tregs.CONCLUSIONS: This trial supports the claims that birch-pollen IT also decreases allergy to foods containing Bet v 1-homologous allergens. Recombinant allergens and DBPCFCs have proven to be useful tools for monitoring the effect of birch-pollen IT on linked food allergies.",

keywords = "Adult, Allergens, Antigens, Plant, Betula, CD4-Positive T-Lymphocytes, Cross Reactions, Desensitization, Immunologic, Double-Blind Method, Female, Food, Food Hypersensitivity, Humans, Immunologic Tests, Lymphocyte Activation, Male, Malus, Plant Proteins, Pollen, Recombinant Proteins, Skin Tests",

author = "S.T.H.P. Bolhaar and M.M. Tiemessen and L. Zuidmeer and {van Leeuwen}, A. and K. Hoffmann-Sommergruber and {Bruijnzeel - Koomen}, C.A.F.M. and L.S. Taams and E.F. Knol and {van Hoffen}, E. and {van Ree}, R. and A.C. Knulst",

year = "2004",

doi = "10.1111/j.1365-2222.2004.1939.x",

language = "English",

volume = "34",

pages = "761--769",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell",

number = "5",

}

Bolhaar, STHP, Tiemessen, MM, Zuidmeer, L, van Leeuwen, A, Hoffmann-Sommergruber, K, Bruijnzeel - Koomen, CAFM, Taams, LS, Knol, EF, van Hoffen, E, van Ree, R & Knulst, AC 2004, 'Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges', Clinical and Experimental Allergy, vol. 34, no. 5, pp. 761-769. https://doi.org/10.1111/j.1365-2222.2004.1939.x

TY - JOUR

T1 - Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges

AU - Bolhaar, S.T.H.P.

AU - Tiemessen, M.M.

AU - Zuidmeer, L.

AU - van Leeuwen, A.

AU - Hoffmann-Sommergruber, K.

AU - Bruijnzeel - Koomen, C.A.F.M.

AU - Taams, L.S.

AU - Knol, E.F.

AU - van Hoffen, E.

AU - van Ree, R.

AU - Knulst, A.C.

PY - 2004

Y1 - 2004

N2 - BACKGROUND: The effect of birch-pollen immunotherapy (IT) on cross-reactive food allergies is controversial.OBJECTIVE: The aim of this study was to investigate the effect of birch-pollen IT on apple allergy and to evaluate recombinant allergens and double-blind placebo-controlled food challenges (DBPCFCs) as monitoring tools.METHODS: Twenty-five adult birch-pollen- and apple-allergic patients were randomly divided into two groups, either receiving birch-pollen IT or symptomatic drugs only. IgE and IgG4 antibodies against birch pollen, apple, natural Bet v 1 and Mal d 1 were measured. In addition, skin prick tests (SPT) were performed using recombinant Bet v 1 (rBet v 1) and Mal d 1 (rMal d 1). Clinical outcome was evaluated by DBPCFC. CD4(+)CD25(+) regulatory T cells (Tregs) were isolated from peripheral blood and tested in functional assays.RESULTS: Birch-pollen IT resulted in a significant decrease of SPT reactivity for rBet v 1 (30-fold) and rMal d 1 (10-fold) already after 3 months. IgG4 antibodies were potently induced against Bet v 1, displaying cross-reactivity to Mal d 1. Visual analogue scale scores decreased >10-fold in 9/13 patients of the IT group, with three patients converting to negative. In the control group, no decrease was observed. Birch-pollen IT did not lead to detectable changes in the number or function of the CD4(+)CD25(+) Tregs.CONCLUSIONS: This trial supports the claims that birch-pollen IT also decreases allergy to foods containing Bet v 1-homologous allergens. Recombinant allergens and DBPCFCs have proven to be useful tools for monitoring the effect of birch-pollen IT on linked food allergies.

AB - BACKGROUND: The effect of birch-pollen immunotherapy (IT) on cross-reactive food allergies is controversial.OBJECTIVE: The aim of this study was to investigate the effect of birch-pollen IT on apple allergy and to evaluate recombinant allergens and double-blind placebo-controlled food challenges (DBPCFCs) as monitoring tools.METHODS: Twenty-five adult birch-pollen- and apple-allergic patients were randomly divided into two groups, either receiving birch-pollen IT or symptomatic drugs only. IgE and IgG4 antibodies against birch pollen, apple, natural Bet v 1 and Mal d 1 were measured. In addition, skin prick tests (SPT) were performed using recombinant Bet v 1 (rBet v 1) and Mal d 1 (rMal d 1). Clinical outcome was evaluated by DBPCFC. CD4(+)CD25(+) regulatory T cells (Tregs) were isolated from peripheral blood and tested in functional assays.RESULTS: Birch-pollen IT resulted in a significant decrease of SPT reactivity for rBet v 1 (30-fold) and rMal d 1 (10-fold) already after 3 months. IgG4 antibodies were potently induced against Bet v 1, displaying cross-reactivity to Mal d 1. Visual analogue scale scores decreased >10-fold in 9/13 patients of the IT group, with three patients converting to negative. In the control group, no decrease was observed. Birch-pollen IT did not lead to detectable changes in the number or function of the CD4(+)CD25(+) Tregs.CONCLUSIONS: This trial supports the claims that birch-pollen IT also decreases allergy to foods containing Bet v 1-homologous allergens. Recombinant allergens and DBPCFCs have proven to be useful tools for monitoring the effect of birch-pollen IT on linked food allergies.

KW - Adult

KW - Allergens

KW - Antigens, Plant

KW - Betula

KW - CD4-Positive T-Lymphocytes

KW - Cross Reactions

KW - Desensitization, Immunologic

KW - Double-Blind Method

KW - Female

KW - Food

KW - Food Hypersensitivity

KW - Humans

KW - Immunologic Tests

KW - Lymphocyte Activation

KW - Male

KW - Malus

KW - Plant Proteins

KW - Pollen

KW - Recombinant Proteins

KW - Skin Tests

U2 - 10.1111/j.1365-2222.2004.1939.x

DO - 10.1111/j.1365-2222.2004.1939.x

M3 - Article

C2 - 15144469

SN - 0954-7894

VL - 34

SP - 761

EP - 769

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 5

ER -

Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges

Abstract

Keywords

Access to Document

Fingerprint

Cite this